RTP Mobile Logo
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

Lung cancer is a devastating disease that accounts for approximately 13% of new cancer cases and more cancer-related deaths among both men and women than any other tumor type. In the year 2015, it is estimated that 221,200 individuals will be diagnosed and 158,040 individuals will die from the disease. The plethora of available cytotoxic chemotherapies exhibiting activity in lung cancer has increased substantially over the past several years, and development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The advent of these next-generation targeted treatments presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms.

This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.


  • Develop an evidence-based strategy for the treatment of localized non-small cell lung cancer (NSCLC), exploring the role of (neo)adjuvant systemic therapy.
  • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the treatment of NSCLC.
  • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and identify therapeutic opportunities to circumvent this process.
  • Communicate the efficacy and safety of crizotinib, ceritinib and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK and ROS1 mutation testing.
  • Devise an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced pan-wild-type NSCLC.
  • Describe emerging data on the efficacy and safety of tumor immunotherapy in lung cancer, and consider this information when counseling patients regarding clinical trial participation.
  • Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data with experimental agents exploiting these targets.
  • Formulate management strategies for small cell lung cancer, considering the contributory roles of local and systemic therapy.
  • Consider the use of multimodality therapy for appropriate patients with mesothelioma who may potentially be cured with this approach.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in lung cancer, and counsel appropriately selected patients about availability and participation.


CME credit is no longer available for this issue


CME credit is no longer available for this issue

This activity consists of a video component. The participant should watch the video.

CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

A William Blackstock, MD
Professor and Chairman
Department of Radiation Oncology
Director, Clinical Research Program
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina

No real or apparent conflicts of interest to disclose.

Julie R Brahmer, MD
Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Advisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Paid Research: AstraZeneca Pharmaceuticals LP; Uncompensated Research: Bristol-Myers Squibb Company.

David E Gerber, MD
Associate Professor
Division of Hematology-Oncology
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C Simmons Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Advisory Committee: Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Contracted Research: ArQule Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Peregrine Pharmaceuticals Inc.

Ramaswamy Govindan, MD
Professor of Medicine
Section of Medical Oncology
Division of Oncology
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements: GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc.

Roy S Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Consulting Agreements: Genentech BioOncology, Lilly, Merck.

Leora Horn, MD, MSc
Associate Professor of Medicine
Assistant Director
Educator Development Program
Vanderbilt University Medical Center
Nashville, Tennessee

Advisory Committee: Bristol-Myers Squibb Company, Clovis Oncology, Helix BioPharma Corp, Puma Biotechnology Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Merck; Contracted Research: Astellas Scientific and Medical Affairs Inc; Honoraria: Boehringer Ingelheim Pharmaceuticals Inc.

Mark G Kris, MD
William and Joy Ruane Chair in Thoracic Oncology
Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committee: Daiichi Sankyo Inc; Consulting Agreements: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology; Contracted Research: Pfizer Inc, Puma Biotechnology Inc; Other Remunerated Activities: Roche Laboratories Inc.

Rogerio C Lilenbaum, MD
Professor of Medicine
Yale School of Medicine
Chief Medical Officer
Smilow Cancer Hospital
Yale Cancer Center
New Haven, Connecticut

Advisory Committee: Celgene Corporation, Genentech BioOncology.

Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Palo Alto, California

Contracted Research: ArQule Inc, Genentech BioOncology, Merck.

Harvey I Pass, MD
Professor of Surgery and Cardiothoracic Surgery
Director, Division of Thoracic Surgery
NYU Langone Medical Center
New York, New York

Contracted Research: Genzyme Corporation.

Charles M Rudin, MD, PhD
Professor and Chief
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Merck.

Mark A Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section
Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania

Advisory Committee: Bristol-Myers Squibb Company, Lilly, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Pfizer Inc, Takeda Oncology; Speakers Bureau: Celgene Corporation, Genentech BioOncology.

Everett E Vokes, MD
John E Ultmann Professor
Chairman, Department of Medicine
University of Chicago Medicine and Biological Sciences
Chicago, Illinois

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, GeneCentric Diagnostics Inc, Genentech BioOncology, Merck, Synta Pharmaceuticals Corp, VentiRx Pharmaceuticals Inc.

MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Foundation Medicine, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: June 2015
Expiration date: June 2016